Advanced search
Publication Cover
Human Vaccines & Immunotherapeutics Volume 18, 2022 - Issue 1
Submit an article Journal homepage
2,023
Views
6
CrossRef citations to date
0
Altmetric
Coronavirus – Letters

Omicron, a new SARS-CoV-2 variant: assessing the impact on severity and vaccines efficacy

Gaurav Joshia School of Pharmacy, Graphic Era Hill University, Dehradun, IndiaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-7812-2871View further author information
ORCID Icon &
Ramarao Podurib GITAM Institute of Pharmacy, GITAM University, Visakhapatnam, IndiaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-8144-349XView further author information
ORCID Icon
Article: 2034458 | Received 07 Jan 2022, Accepted 22 Jan 2022, Published online: 03 Mar 2022

References

  • Technical Advisory Group on Virus Evolution. Update on Omicron. https://www.who.int/news/item/28-11-2021-update-on-omicron.
  • Zinatizadeh MR, Zarandi PK, Zinatizadeh M, Yousefi MH, Amani J, Rezaei N. Efficacy of MRNA, adenoviral vector, and perfusion protein COVID-19 vaccines. Biomed Pharmacother. 2022;146:112527. doi:10.1016/j.biopha.2021.112527.
  • Dhawan M, Priyanka OPC. Omicron SARS-CoV-2 variant: reasons of emergence and lessons learnt. Int J Surg. 2022;97:106198. doi:10.1016/j.ijsu.2021.106198.
  • Cele S, Jackson L, Khan K, Khoury D, Moyo-Gwete T, Tegally H, Scheepers C, Amoako D, Karim F, Bernstein M, et al. SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection. medRxiv Prepr Serv Heal Sci. 2021;10:11.
  • Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, Gower C, Kall M, Groves N, O’Connell A-M. Effectiveness of COVID-19 vaccines against the Omicron (B. 1.1. 529) variant of concern. MedRxiv. 2021.
  • England PH. SARS-CoV-2 variants of concern and variants under investigation in England. Tech Brief. 2021;12:1–2. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1009243/Technical_Briefing_20.pdf.
  • Pfizer. Pfizer and biontech provide update on Omicron variant. [ accessed 2022 Jan 4]. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-provide-update-omicron-variant.
  • Collie S, Champion J, Moultrie H, Bekker L-G, Gray G. Effectiveness of BNT162b2 vaccine against Omicron variant in South Africa. N Engl J Med. 2021. doi:10.1056/NEJMc2119270.
  • Buchan SA, Chung H, Brown KA, Austin PC, Fell DB, Gubbay JB, Nasreen S, Schwartz KL, Sundaram ME, Tadrous M, et al. Effectiveness of COVID-19 vaccines against Omicron or delta infection. medRxiv. 2022:2021. doi:10.1101/2021.12.30.21268565.
  • Hansen CH, Schelde AB, Moustsen-Helm IR, Emborg H-D, Krause TG, Mølbak K, Valentiner-Branth P; Institut, on behalf of the I. D. P. G. Vaccine effectiveness against SARS-CoV-2 infection with the Omicron or delta variants following a two-dose or booster BNT162b2 or MRNA-1273 vaccination series: a Danish cohort study. medRxiv. 2021;2021. doi:10.1101/2021.12.20.21267966.
  • Joshi G, Borah P, Thakur S, Sharma P, Mayank, Poduri R. Exploring the COVID-19 vaccine candidates against SARS-CoV-2 and its variants: where do we stand and where do we go? Hum Vaccin Immunother. 2021:1–27. doi:10.1080/21645515.2021.1995283.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.